Journal of Psychopharmacology最新文献

{"title":"Adverse drug reactions associated with psychotropic medications combined with versus without lithium: A case/control pharmacovigilance analysis.","authors":"Waldemar Greil, Mateo de Bardeci, Nadja Nievergelt, Andreas Erfurth, Gregor Hasler, Katja Cattapan, Stefan Bleich, Sermin Toto, Johanna Seifert, Renate Grohmann, Georgios Schoretsanitis","doi":"10.1177/02698811261488471","DOIUrl":"https://doi.org/10.1177/02698811261488471","url":null,"abstract":"<p><strong>Background: </strong>We assessed the association between different adverse drug reactions (ADRs) and patients with versus without lithium co-medication using data from the European drug surveillance program AMSP (German: \"Arzneimittelsicherheit in der Psychiatrie,\" i.e. Drug Safety in Psychiatry)Methods:We conducted a case/non-case pharmacovigilance study using AMSP data on ADRs from patients treated in psychiatric hospitals in Germany, Austria, and Switzerland. We performed a disproportionality analysis of reports of severe ADRs from patients with versus without lithium co-medication calculating reporting odds ratios (RORs). Additional analyses included comparisons with distinct pharmacological classes, reports where the imputation grade for ADRs was probable or certain, and where ADR rates were related to exposed patients.</p><p><strong>Results: </strong>In 8609 patients, lithium-treated patients (<i>n</i> = 720) were less often associated with weight gain, dyskinesia, suicidality (as an ADR), hyponatremia, and mortality, but more often associated with various types of neurotoxicity (<i>p</i> < 0.05 in all cases). Parkinson's symptoms (ROR 1.8), tremor (ROR 4.6), serotonergic ADRs (ROR 3.0), ataxia or myoclonus (each, ROR 2.7), as well as drug-drug interactions leading to intoxication (ROR 26.3, <i>p</i> < 0.05 in all cases). When stratifying by pharmacological class, hyponatremia was more frequent in patients receiving different pharmacological classes (<i>p</i> < 0.05 in all cases), whereas neurotoxicity and lithium intoxications were more frequently reported in lithium comedication groups (<i>p</i> < 0.05 in all cases).</p><p><strong>Conclusions: </strong>Patients treated with lithium are associated with a reduced reporting of hyponatremia, but to an increased reporting of neurotoxicity, although findings represent reporting associations, rather than incidence estimates or causal effects.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261488471"},"PeriodicalIF":5.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis.","authors":"Gianluca A Florineth, Anna L Boeker, Tobias Bracht, Alexander Wopfner, Niklaus Denier, Kristina Adorjan, Felix Müller, Leila M Soravia","doi":"10.1177/02698811261490221","DOIUrl":"https://doi.org/10.1177/02698811261490221","url":null,"abstract":"<p><strong>Background: </strong>Psilocybin-assisted therapy (PAT) has emerged as a promising intervention for alcohol use disorder (AUD), yet contemporary clinical evidence has not been systematically synthesized to validate its clinical utility and safety profile.</p><p><strong>Methods: </strong>Contemporary clinical trials of PAT for AUD were identified systematically from PubMed, PsycINFO, and Scopus by two independent reviewers. Random-effects meta-analyses were conducted to synthesize within-group pre-post changes and between-group differences from randomized controlled trials (RCTs). Primary outcomes included continuous drinking measures and abstinence rates; secondary outcomes included adverse events (AEs).</p><p><strong>Results: </strong>Six trials (<i>N</i> = 202) met inclusion criteria (3 RCTs). PAT produced significant within-group reductions across all drinking outcomes that were sustained at mid- to long-term follow-up (4-28 weeks). Compared to controls, psilocybin demonstrated moderate short-term advantages for drinks per day (standardized mean differences (SMD) = 0.48; <i>p</i> = 0.004), percent drinking days (SMD = 0.50; <i>p</i> = 0.009), and percent heavy drinking days (SMD = 0.39; <i>p</i> = 0.020). At mid- to long-term follow-up, only percent drinking days remained significantly superior (SMD = 0.41; <i>p</i> = 0.032). Psilocybin-treated patients had significantly higher odds of maintaining abstinence compared to controls (OR = 2.78; <i>p</i> = 0.029). AEs were predominantly mild and transient.</p><p><strong>Conclusions: </strong>Current evidence for PAT in AUD is mixed but suggests preliminary signals of efficacy for reducing alcohol consumption and increasing the odds of maintaining long-term abstinence. The intervention was well-tolerated with a favorable safety profile, supporting its potential as a novel treatment option.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261490221"},"PeriodicalIF":5.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Δ⁹-tetrahydrocannabinol on affiliative social behaviour: A systematic review of rodent studies.","authors":"Mashal Ahmed, Christina F Pereira, Laura M Best, Raesham Mahmood, Tony P George, Bernard Le Foll, Isabelle Boileau, Stefan Kloiber","doi":"10.1177/02698811261478615","DOIUrl":"https://doi.org/10.1177/02698811261478615","url":null,"abstract":"<p><strong>Introduction: </strong>Affiliative social behaviour is critical for survival and well-being and is shaped by complex neurobiological systems, including the endocannabinoid system (ECS). Δ⁹-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, is a partial agonist at cannabinoid receptors and directly modulates ECS signaling. Given increasing cannabis use globally, understanding the effects of THC on social functioning is essential.</p><p><strong>Methods: </strong>We conducted a systematic review of preclinical studies indexed in MEDLINE and PsycINFO to examine the effects of THC on social behaviour in wild-type (WT) rodents and rodent social impairment models (SIM). Forty-nine studies encompassing 146 experiments were included. Risk of bias (RoB) was assessed using SYRCLE's tool.</p><p><strong>Results: </strong>In WT rodents, THC generally reduced social behaviour, particularly following acute or adolescent exposure at moderate-to-high doses. SIM results were mixed: while low-dose THC sometimes improved social behaviour in schizophrenia-related models, higher doses often worsened deficits or had no effect. Outcomes varied by dose, sex, developmental timing, and experimental model. RoB assessment revealed insufficient reporting for nearly half of the included studies.</p><p><strong>Conclusion: </strong>These findings highlight the complexity of THC's behavioural effects and suggest a need for more rigorous, sex-balanced preclinical research. Moreover, suboptimal methodological quality across studies hinders replicability and generalizability. More thorough and streamlined reporting is needed to support the translational validity of this area of research. As interest grows in ECS-targeted therapies for psychiatric disorders, understanding how THC modulates affiliative social behaviour under different conditions will be essential to inform safe and effective clinical strategies.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261478615"},"PeriodicalIF":5.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proper assessment of the response to a test drug needs a treatment-free control group in the experimental design.","authors":"S Clare Stanford, Simon T Bate, Manuel Berdoy","doi":"10.1177/02698811261488491","DOIUrl":"https://doi.org/10.1177/02698811261488491","url":null,"abstract":"<p><p>In preclinical biomedical research, the response elicited by a test drug is commonly evaluated relative to the response produced by its vehicle, with the difference assumed to represent the magnitude of the drug's action. However, there are many reports that the administration of vehicle can provoke a measurable response. For vehicles that are presumed to be inert (e.g. saline), this likely arises from the stress of the administration procedure itself. However, for drugs that are poorly soluble in water, there is extensive evidence that their vehicles can have profound physiological and toxic effects (including neurotoxicity). More complex interactions are also possible, whereby the effect of vehicle administration modifies the profile of the response to the test drug. This article discusses these confounders and argues that proper interpretation of the response to a drug treatment, and successful translation of novel compounds into the clinic, rests on establishing whether the vehicle itself affects the response of interest or modifies the response of the test drug. To investigate these possibilities, the experimental design needs to include a context-matched, treatment-free control group, as well as a vehicle-treated control group. We argue that only if the response of interest in the treatment-free control group is confirmed to be statistically equivalent to that of the vehicle-treated control group, is it appropriate to proceed with further experiments without including treatment-free control samples.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261488491"},"PeriodicalIF":5.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review\".","authors":"Nehal Taj Wali Khan, Hilal Khan, Bilal Ahmed, Syed Hassan Ali","doi":"10.1177/02698811261490197","DOIUrl":"https://doi.org/10.1177/02698811261490197","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261490197"},"PeriodicalIF":5.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes.","authors":"Jennifer Jones, Joseph Redding, Emily Amador","doi":"10.1177/02698811261488486","DOIUrl":"https://doi.org/10.1177/02698811261488486","url":null,"abstract":"<p><strong>Background: </strong>Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches. Ketamine, a rapid-acting glutamate receptor antagonist with neuroplasticity-enhancing properties, has shown promise in the treatment of other substance use disorders. Combining ketamine with motivational enhancement therapy (MET) may complement behavioral treatment in TUD by facilitating cognitive and psychological flexibility while strengthening individuals' ability to quit smoking.</p><p><strong>Objective: </strong>The primary aim of this open-label pilot study was to evaluate the feasibility and preliminary clinical outcomes of ketamine treatments delivered in conjunction with MET for smoking cessation in individuals with TUD.</p><p><strong>Methods: </strong>Seven cigarette smokers (ages 29-64) with a history of unsuccessful quit attempts underwent three weekly intramuscular ketamine sessions (0.71 mg/kg) combined with MET. Feasibility, the primary outcome, was assessed by study completion rates. Secondary outcomes included changes in smoking patterns, craving, nicotine dependence, withdrawal, and motivation to quit.</p><p><strong>Results: </strong>All participants completed the interventional sessions. Ketamine sessions were well-tolerated, and no adverse events other than the expected transient psychoactive effects were observed. Cigarette consumption decreased, accompanied by reductions in nicotine craving. Withdrawal symptoms, nicotine dependence severity, and motivation to quit remained stable.</p><p><strong>Conclusions: </strong>Ketamine-enhanced psychotherapy for TUD was feasible and was associated with reductions in smoking and craving. These preliminary findings support further trials investigating ketamine's potential to enhance behavioral interventions for addiction.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261488486"},"PeriodicalIF":5.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review.","authors":"Victoria Yue Tan, Sabrina Wong, Gia Han Le, Angela T H Kwan, Melanie C Zhang, Yang Jing Zheng, Kayla Teopiz, Christine E Dri, Roger Ho, Stavroula Bargiota, Bing Cao, Roger S McIntyre","doi":"10.1177/02698811261488466","DOIUrl":"https://doi.org/10.1177/02698811261488466","url":null,"abstract":"<p><strong>Background: </strong>Many proteins integral to psychotropic agents' pharmacokinetics (PK) and pharmacodynamics (PD) exhibit circadian variation in expression and function. Chronopharmacology examines the effect of circadian systems on the pharmacology of drugs. Herein, we review the impact of circadian rhythm on drug-metabolizing enzymes and target receptors, with implications for the chronopharmacology of anticonvulsants, antidepressants, and antipsychotics.</p><p><strong>Methods: </strong>Systematic searches of MEDLINE, Embase, PsycINFO, AMED, and JBI EBP were conducted from inception to September 2025 using terms related to \"circadian rhythm,\" \"chronopharmacology,\" and \"psychotropic agents.\" Preclinical and clinical studies investigating circadian-aligned dosing effects on anticonvulsant, antidepressant, or antipsychotic PK/PD were included.</p><p><strong>Results: </strong>Eight preclinical and one clinical study met inclusion criteria. Preliminary evidence suggests that circadian timing may influence the pharmacology of select psychotropic agents. Circadian timing influenced valproic acid PK and antiseizure activity in preclinical seizure models, whereas the single clinical study demonstrated differences in serum valproate concentrations but not seizure outcomes. For antidepressants (i.e., imipramine, milnacipran, fluoxetine, venlafaxine, bupropion), dose-timing altered monoaminergic PD measures in preclinical studies, although the relationship between these findings and antidepressant efficacy remains uncertain. Limited evidence suggests that circadian timing may influence the metabolic effects of quetiapine in mice.</p><p><strong>Conclusion: </strong>Current evidence provides preliminary support that circadian rhythm may differentially affect the pharmacology of select psychotropic agents. Whether the foregoing translates into clinically meaningful differences in efficacy, tolerability, and/or posology of the evaluated agents/classes requires systematic evaluation. Given that evidence is predominantly preclinical, further studies using clinically relevant repeated-dose regimens and disease-relevant animal models are required.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261488466"},"PeriodicalIF":5.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?","authors":"Rajeev Krishnadas, I Lam Leong, Joanna Fraczek, Emilio Fernandez-Egea, Lena Palaniyappan","doi":"10.1177/02698811261488465","DOIUrl":"https://doi.org/10.1177/02698811261488465","url":null,"abstract":"<p><p>Clozapine is the most effective treatment for treatment-resistant schizophrenia, yet it is often introduced late. This article proposes a critical period hypothesis, arguing that clozapine is most effective when started during a stage of illness in which network plasticity and synaptic substrate are still partially preserved. We outline a neurobiological continuum from first-line antipsychotic response to ultra-treatment resistance, emphasising dynamic changes in dopamine, glutamate, gamma-aminobutyric acid and muscarinic cholinergic systems. Observational studies suggest that earlier clozapine initiation is associated with better outcomes, particularly for negative symptoms and functioning. The hypothesis supports earlier recognition of treatment resistance and reduced avoidable delay.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261488465"},"PeriodicalIF":5.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state.","authors":"Maria Niedernhuber, Dila Suay, Bigna Lenggenhager, Michael Müller, Milan Scheidegger, Dario Dornbierer, Helena Aicher","doi":"10.1177/02698811261481062","DOIUrl":"https://doi.org/10.1177/02698811261481062","url":null,"abstract":"<p><strong>Background: </strong>Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility. Beyond temporal variability, it is an open question whether psychedelics impact the characteristics of transient neural state sequences themselves.</p><p><strong>Aims: </strong>Our goal was to assess how an ayahuasca-inspired formulation (intranasal N,N-Dimethyltryptamine (DMT) and buccal harmine) modulates parameters of neural state sequences close to the peak of the psychedelic state.</p><p><strong>Methods: </strong>In a double-blind, randomised, placebo-controlled Electroencephalography (EEG) study, participants (<i>n</i> = 25) were administered the following interventions on separate testing days: (1) a DMT/harmine formulation; (2) harmine alone and (3) a placebo. We used EEG microstate analysis to compare the neural dynamics between the three conditions.</p><p><strong>Results/outcomes: </strong>Compared to harmine and placebo, DMT/harmine was linked to reduced microstate duration but increased microstate occurrence and complexity. Higher first-order Markov statistics revealed that transition sequences became less random when DMT/harmine was administered.</p><p><strong>Conclusions/interpretation: </strong>Our finding that DMT/harmine is associated with more complex and predictable neural state sequences as well as accelerated state transitions is consistent with models of increased metastability and signal diversity. By revealing a more diverse repertoire of neural state sequences under DMT/harmine, our findings improve our understanding of neural dynamics in psychedelic states.</p><p><strong>Clinical trial registration: </strong>Neurodynamics of prosocial emotional processing following serotonergic stimulation with N,N-DMT and harmine in healthy subjects. https://clinicaltrials.gov/ct2/show/NCT04716335.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261481062"},"PeriodicalIF":5.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences.","authors":"Rebecca Ehrenkranz, Nathan D Sepeda, Sean P Goldy, Brandon M Weiss, Praachi Tiwari, Arozo Azimi, David B Yaden","doi":"10.1177/02698811261473405","DOIUrl":"https://doi.org/10.1177/02698811261473405","url":null,"abstract":"<p><strong>Background: </strong>The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden.</p><p><strong>Aims: </strong>Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF).</p><p><strong>Methods: </strong>Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals.</p><p><strong>Results: </strong>We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning.</p><p><strong>Conclusions: </strong>We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261473405"},"PeriodicalIF":5.3,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}